John D. Jr. Shaughnessy

John D. Jr. Shaughnessy's AcademicInfluence.com Rankings

Biology

#13073

World Rank

#16598

Historical Rank

Molecular Biology

#2164

World Rank

#2198

Historical Rank

Biochemistry

#2256

World Rank

#2403

Historical Rank

biology Degrees

Download Badge

Biology

Why Is John D. Jr. Shaughnessy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John D. Jr. Shaughnessy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (2003) (1433)
The molecular classification of multiple myeloma. (2006) (1012)
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. (2007) (976)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. (2006) (839)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review (2009) (813)
Absence Epilepsy in Tottering Mutant Mice Is Associated with Calcium Channel Defects (1996) (775)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. (2006) (731)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. (2002) (662)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. (2005) (661)
Genetics and Cytogenetics of Multiple Myeloma (2004) (566)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. (2001) (553)
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia (1996) (528)
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models (2010) (456)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. (2009) (454)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma (2008) (450)
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. (2007) (445)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. (2006) (416)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. (2006) (414)
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. (2007) (374)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. (2006) (360)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. (2006) (360)
The role of Dickkopf-1 in bone development, homeostasis, and disease. (2009) (353)
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. (2000) (340)
Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias (1996) (339)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 (2007) (321)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy (2004) (307)
Treatment of multiple myeloma. (2004) (283)
Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma (2009) (254)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. (2008) (246)
Leukaemia disease genes: large-scale cloning and pathway predictions (1999) (244)
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. (2008) (237)
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. (2001) (220)
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. (2003) (207)
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. (2010) (205)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. (2003) (197)
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. (2005) (196)
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 (2010) (188)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma (2011) (187)
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. (2005) (185)
Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy (2007) (183)
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. (2007) (181)
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. (2000) (181)
High heparanase activity in multiple myeloma is associated with elevated microvessel density. (2003) (177)
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. (2007) (176)
Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma (2006) (174)
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. (2003) (171)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 (2008) (167)
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). (2014) (166)
Heparanase Enhances Syndecan-1 Shedding (2007) (165)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma (2009) (163)
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. (2002) (163)
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. (2008) (161)
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II (2003) (159)
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. (2008) (159)
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. (2009) (154)
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma (2005) (153)
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. (2007) (153)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. (2011) (150)
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report (2004) (149)
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. (2008) (142)
Wnts induce migration and invasion of myeloma plasma cells. (2005) (142)
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma (2008) (142)
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. (2007) (132)
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. (2006) (129)
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. (2003) (129)
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. (2008) (129)
Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping (1998) (126)
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma (2008) (125)
Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. (2012) (124)
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. (2007) (122)
Thalidomide induces limb deformities by perturbing the Bmp/Dkkl/Wnt signaling pathway (2007) (118)
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. (2003) (114)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. (2009) (112)
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy (2004) (110)
Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q (2005) (106)
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. (2010) (106)
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. (2010) (106)
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. (2008) (105)
The molecular characterization and clinical management of multiple myeloma in the post-genome era (2009) (101)
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. (2008) (100)
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling (2007) (100)
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. (2008) (99)
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. (2004) (96)
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy (2012) (95)
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. (2009) (93)
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma (2001) (93)
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. (2008) (92)
Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts (2008) (92)
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. (2007) (89)
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. (2010) (83)
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk disease (2003) (81)
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis (2009) (77)
Evi27 encodes a novel membrane protein with homology to the IL17 receptor (2000) (74)
Human Placenta‐Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone (2011) (74)
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. (2009) (72)
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells (2006) (71)
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. (2008) (71)
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. (1998) (69)
Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels (1995) (68)
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma (2005) (67)
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols (2012) (67)
Predicting cancer susceptibility from single-nucleotide polymorphism data: a case study in multiple myeloma (2005) (66)
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease (2007) (66)
Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. (1993) (63)
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease (2013) (60)
Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations (2006) (59)
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. (2012) (58)
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling (2004) (56)
Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma (2008) (54)
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling (2003) (53)
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival (2006) (52)
Advances in Biology and Therapy of Multiple Myeloma (2013) (51)
In vitro exposure to cadmium in rat L6 myoblasts can result in both enhancement and suppression of malignant progression in vivo. (1996) (50)
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. (2003) (49)
Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine (2012) (48)
Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1 (1999) (46)
Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels (2013) (46)
First thalidomide clinical trial in multiple myeloma: a decade. (2008) (46)
Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray (2004) (42)
cDNA cloning, expression analysis, and chromosomal localization of a gene with high homology to wheat eIF-(iso)4F and mammalian eIF-4G. (1997) (42)
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. (2010) (41)
Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma (2007) (41)
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis (2009) (40)
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16·3;q32) in multiple myeloma (2004) (40)
Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone (2010) (39)
Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. (2010) (39)
Prediction of cytogenetic abnormalities with gene expression profiles. (2012) (38)
Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients (2004) (37)
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression (2006) (37)
CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma (2008) (36)
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma (2012) (36)
Role of osteoblast suppression in multiple myeloma (2006) (35)
The Arkansas approach to therapy of patients with multiple myeloma. (2007) (35)
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage‐fusion‐bridge cycles of a 1q12∼23 amplicon (2009) (35)
MDS‐type abnormalities within myeloma signature karyotype (MM‐MDS): only 13% 1‐year survival despite tandem transplants (2003) (35)
Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas (1995) (34)
The Bcl‐2 family member Bfl‐1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti‐apoptotic factor for myeloma cells (2004) (31)
Cure of myeloma: hype or reality? (2005) (31)
CKS 1 B , overexpressed in aggressive disease , regulates multiple myeloma growth and survival through SKP 2-and p 27 Kip 1-dependent and-independent mechanisms (2007) (30)
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. (2011) (30)
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma (2011) (30)
Establishment and exploitation of hyperdiploid and non‐hyperdiploid human myeloma cell lines (2007) (29)
The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. (2003) (29)
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease (2009) (28)
Gene expression profiles of primary HPV 16-and HPV 18-infected early stage cervical cancers and normal cervical epithelium : identification of novel candidate molecular markers for cervical cancer diagnosis and therapy (2004) (28)
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. (2011) (27)
Proteasome inhibitors and bone disease. (2012) (27)
Gene expression profiling and multiple myeloma. (2005) (26)
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. (2007) (25)
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. (2009) (25)
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. (2009) (25)
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. (2014) (24)
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma (2017) (23)
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma (2017) (23)
Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma (2012) (23)
Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH (2002) (22)
Mouse chromosomal location of three epithelial sodium channel subunit genes and an apical sodium chloride cotransporter gene. (1996) (22)
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma (2008) (20)
Using genomics to identify high-risk myeloma after autologous stem cell transplantation. (2006) (20)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (19)
Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma (2009) (19)
Primer on medical genomics. Part IX: scientific and clinical applications of DNA microarrays--multiple myeloma as a disease model. (2003) (19)
Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 (2012) (19)
High-dose therapy and immunomodulatory drugs in multiple myeloma. (2002) (18)
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity (2013) (18)
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling. (2003) (18)
Evaluation of Multiple Models to Distinguish Closely Related Forms of Disease Using DNA Microarray Data: an Application to Multiple Myeloma (2004) (18)
Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (16)
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. (2003) (16)
Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5 (2008) (15)
Expression and mutation status of candidate kinases in multiple myeloma (2008) (15)
Chromosome 13 deletion in myeloma. (1999) (14)
Sample Size Calculations Based on Ranking and Selection in Microarray Experiments (2008) (13)
Global Gene Expression Profiling in the Study of Multiple Myeloma (2003) (13)
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
IgM-expressing Waldenstrom's macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo (2007) (12)
Overview of biological database mapping services for interoperation between different 'omics' datasets (2011) (12)
A novel c-myc-activating reciprocal T(12;15) chromosomal translocation juxtaposes S alpha to Pvt-1 in a mouse plasmacytoma. (1994) (11)
Cancer: An unexpected addiction (2008) (11)
The neurofibromatosis type 1 (NF1) tumor suppressor gene and myeloid leukemia. (1996) (11)
Integrating cytogenetics and gene expression profiling in the molecular analysis of Multiple Myeloma (2002) (10)
Retroviral enhancer insertion 5' of c-myc in two translocation-negative mouse plasmacytomas upregulates c-myc expression to different extents. (1993) (10)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (10)
Heterologous Tissue Culture Expression Signature Predicts Human Breast Cancer Prognosis (2007) (10)
Clustering of significant genes in prognostic studies with microarrays: Application to a clinical study for multiple myeloma (2008) (10)
A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax (2016) (10)
The ephrinB 2 / EphB 4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth (2009) (10)
CGO: utilizing and integrating gene expression microarray data in clinical research and data management (2002) (10)
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia (2007) (9)
Identification of Three Novel Chromosomal Translocation Partners Involving the Immunoglobulin Loci in Newly Diagnosed Myeloma and Human Myeloma Cell Lines. (2005) (9)
Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression (2021) (9)
Total Therapy 3 (TT3) Incorporating VelcadeR (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T). (2005) (9)
Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response. (2004) (8)
Multiple myeloma. (2004) (8)
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression (2015) (8)
Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM) (2005) (8)
An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups. (2006) (8)
Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile (2011) (7)
Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia (2018) (7)
Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3. (2011) (7)
High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. (2006) (7)
Expression and mutation status of candidate kinases in multiple myeloma (2007) (7)
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM) (2007) (6)
TP53 Gene Expression, Correlated with 17p13 Deletion, Is a Significant and Independent Adverse Prognostic Factor in Multiple Myeloma Treated with High-Dose Therapy and Auto-Transplants. (2006) (6)
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival. (2005) (6)
CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody. (2006) (6)
Co‐amplification of c‐myc/pvt‐1 in immortalized mouse b‐lymphocytic cell lines results in a novel pvt‐1/aj‐l transcript (1993) (5)
Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma (2008) (5)
Glucocorticoid Receptor Expression Correlates with Clinical Outcome in Myeloma Patients Treated with Glucocorticoid-Containing Regimens. (2008) (5)
A restriction fragment length polymorphism at murine Glud locus co-segregates with Rib-1, Es-10, and Tcra on chromosome 14. (1989) (5)
Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis. (2004) (5)
FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls. (2004) (5)
Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 (2008) (5)
Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease (2010) (4)
Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy (2008) (4)
MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis. (2004) (4)
Interphase FISH-Defined Amplification of Chromosome 1q21 (AMP1q21) Identify High-Risk Subsets among Patients with Multiple Myeloma (MM) Lacking Metaphase Cytogenetic Abnormalities (CA). (2005) (4)
PHF19 inhibition as a therapeutic target in multiple myeloma. (2021) (4)
SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS, (2011) (4)
Decoupling of DNA excision repair and RNA transcription in translocation breaksite regions of plasmacytoma-susceptible BALB/cAnPt mice. (1997) (4)
Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM). (2005) (4)
Going with the flow, and beyond, in myeloma. (2008) (3)
Developmental therapeutics for multiple myeloma--a road map for the future. (2001) (3)
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma (2022) (3)
Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease (2011) (3)
Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4 (2010) (3)
In vivo changes in gene expression profiles (GEP) after bortezomib (V) for multiple myeloma (MM): Differential effects on plasma cells (PC) and micro-environment (ME). (2006) (3)
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B-cell malignancies. (2021) (3)
Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak. (2009) (3)
Genes associated with immunoglobulin V(D)J recombination are linked on mouse chromosome 2 and human chromosome 11 (2004) (3)
Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma. (2005) (3)
The Genetic Contribution to the Aetiology of Thalidomide Associated VTE. (2006) (3)
Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient. (2005) (3)
Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1 (2006) (3)
Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype, (2011) (3)
Molecular Profiling of Multiple Myeloma Running Head: Molecular Analysis of Myeloma Section: Neoplasia (2001) (2)
Loss of Chemokine Receptor Expression and Tetraspanins Is Correlated with Extramedullary Disease In Multiple Myeloma (2010) (2)
Multiple myeloma. (2018) (2)
SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM). (2009) (2)
Myeloma Cell Interaction with Mesenchymal Stem Cells: Heterogeneity of Myeloma Cell Survival and Gene Expression Studies (2008) (2)
Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis. (2005) (2)
Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis (2011) (2)
Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene PSMD4. (2010) (2)
Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma. (2016) (2)
High-resolution assessment of chromosomal gains and losses in multiple myeloma tumors from bortezomib clinical trial (2008) (2)
Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts (2011) (2)
Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM. (2005) (2)
Prevalence of interleukin-6 receptor polymorphism in Castleman disease and association with increased soluble interleukin-6 receptor levels. (2011) (2)
Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures. (2007) (2)
progression following tandem stem cell transplantation MGUS to relapsed myeloma and is related to prognosis and disease detected by fluorescence in situ hybridization: Incidence increases from Frequent gain of chromosome band 1q21 in plasma cell dyscrasias (2013) (2)
Myeloma is on the move (2004) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III. (2004) (2)
Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). (2010) (2)
High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2). (2004) (2)
Interphase FISH of Chromosome 1 and 13 in Newly Diagnosed Myeloma and the Disease Prognosis (2009) (1)
Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma (2021) (1)
Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma. (2005) (1)
Abstract 2772: BCL-2 family expression profiling may identify distinct molecular subtypes of multiple myeloma with increased susceptibility to single agent Venetoclax (2017) (1)
A Gene Expression-Based Risk Stratification Model Developed in Newly Diagnosed Multiple Myeloma Treated with High Dose Therapy Is Predictive of Outcome in Relapsed Disease Treated with Single Agent Bortezomib. (2007) (1)
Molecularly Classified High Risk Myeloma Cells with Low ROS Levels and High Nestin Expression Have High Proliferation Index and GEP80 Score (2011) (1)
Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP). (2009) (1)
The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma (2000) (1)
DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation. (2006) (1)
Gene Expression Profiling (GEP) of Purified Plasma Cells at Baseline and 48hr after-Dexamethasone (D) or Thalidomide (T) Improve Outcome Predicition of Baseline GEP Alone in Patients with Multiple Myeloma (MM) Treated with Total Therapy 2 (TT2). (2005) (1)
AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. (2022) (1)
Molecular Indicators of High-Risk Disease. (2008) (1)
Gene expression profiling (GEP) of cd 138-purified plasma cells (pc) in previously treated multiple myeloma (PTMM): Validating prognostic models developed in newly diagnosed MM (NDMM). (2009) (1)
Dkk1 blocks Wnt-induced osteoprotegerin production in osteoblast progenitors in multiple myeloma (2007) (1)
Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes (2010) (1)
APRIL showers cause CLL and myeloma to flower (2005) (1)
A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma. (2008) (1)
Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex). (2005) (1)
Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103 (2008) (1)
Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma. (2008) (1)
Proteasome Inhibitor, Bortezomib Induces Mesenchymal Stem Cells toward Osteoblast Differentiation through Wnt-Independent Activation of Beta-catenin/TCF Signaling (2008) (1)
Erratum: Expression and mutation status of candidate kinases in multiple myeloma (Leukemia (2007) vol. 21 (1124-1127) 10.1038/sj.leu.2404612) (2008) (1)
Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy (2014) (1)
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable (2003) (1)
Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles (2011) (1)
Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab. (2009) (1)
Clinical use of genomics in multiple myeloma. (2006) (1)
Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse. (2005) (1)
DKK1 is an Immediate Early Gene in Multiple Myeloma Cells Modulated by Cell Density and IL-6 (2010) (1)
The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features. (2004) (1)
Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients. (2005) (1)
Effect of race, age, and gender on prognosis in total therapy protocols for multiple myeloma. (2010) (1)
Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC) (2011) (1)
Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma (2010) (1)
Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease. (2007) (1)
The Gene Expression Signatures (GEP) of Whole Bone Marrow Biopsies (Bx) from Patients with Multiple Myeloma (MM) in Remission Reflect Disease Risk and Therapy. (2005) (1)
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021) (1)
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. (2022) (1)
NSC 338258 Represents a Novel Anti-Neoplastic Agent for the Treatment of Multiple Myeloma. (2006) (1)
Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (1)
OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma (2008) (1)
On the Molecular Mechanism of DKK1 Inhibition of Osteoblast Differentiation in Multiple Myeloma. (2006) (1)
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma (2011) (1)
Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo. (2009) (1)
Extramedullary disease (EMD): A common terminal pathway in multiple myeloma (MM) progression. (2011) (1)
Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1 (2012) (1)
for personalized and risk adapted treatment in multiple myeloma (2010) (1)
Proteasome inhibitors: introduction. (2012) (0)
Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC). (2010) (0)
A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow. (46.16) (2012) (0)
variable in terms of both onset and duration in Total Therapy protocols Complete remission in multiple myeloma examined as time-dependent (2012) (0)
Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance. (2005) (0)
Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols (2010) (0)
Proteomic Profiling of Multiple Myeloma: Correlation of Protein and Gene Expression Data. (2008) (0)
Smoldering multiple myeloma. (2007) (0)
Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma (2011) (0)
in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities, (2013) (0)
Predictive Biomarkers and Personalized Medicine DevelopingandValidatingContinuousGenomicSignatures in Randomized Clinical Trials for Predictive Medicine (2012) (0)
Molecular determinants of myeloma bone disease by use thereof. (2003) (0)
study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after (2013) (0)
Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2). (2006) (0)
Under-Representation of Black Patients with Multiple Myeloma in Studies Supporting International Myeloma Working Group Guidelines (2022) (0)
Clinical Research Focused on Supportive Care in Multiple Myeloma: A Cross Sectional Analysis (2022) (0)
progression following tandem stem cell transplantation MGUS to relapsed myeloma and is related to prognosis and disease hybridization : Incidence increases from in situ detected by fluorescence Frequent gain of chromosome band 1 q 21 in plasma cell dyscrasias (2006) (0)
Gene Expression Profiling (GEP) in Multiple Myeloma (MM): Comparison of Purified MM Cells (PMM), Random Bone Marrow Biopsies (RBX) and Fine Needle Biopsies from Focal Lesions (FNBX). (2005) (0)
Reply to J. Mehta (2011) (0)
Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression. (2012) (0)
Moloney murine leukemia virus integration 1060 base pairs 5' of c-myc exon 1 in a plasmacytoma without a chromosomal translocation. (1990) (0)
Vaccination With MAGE-3 Protein Induces A Potent Immune Response in A Healthy Donor Which Can Be Adoptively Transferred to A Multiple Myeloma Patient and Boosted by Further Vaccination (2005) (0)
Prognosis in Multiple Myeloma (MM): Characterization of “Losers” (L) in Good Risk and “Winners” (W) in High Risk Disease. (2005) (0)
Cytokine Pathways in Myeloma Growth and Survival (2009) (0)
Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma. (2006) (0)
P-122: Racial differences in spinal cord compression related hospitalizations in patients with multiple myeloma: a population based study (2022) (0)
Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease, (2011) (0)
Marked efficacy of rituximab in two patients with Waldenstrom macroglobulinemia-like multiple myeloma. (2012) (0)
PET and MRI correlation with molecular markers of disease aggressiveness in multiple myeloma (2009) (0)
A Novel Mechanism of Action of Bortezomib: Proteasome Inhibition Down-Regulates HLA-Class I on Myeloma and Enhances NK Cell-Mediated Lysis. (2007) (0)
High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development. (2009) (0)
A167 BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells (2009) (0)
Abstract 4112: E-cadherin regulates cell adherence and β-catenin/TCF signaling in multiple myeloma. (2013) (0)
Exomic microRNA Profiling of Bone Marrow Aspirate Plasma and Comparison with mRNA Profiles Used in the Clinical Management of Multiple Myeloma (2014) (0)
Evaluation of NCAM and DKK1 Expression in Multiple Myeloma and MGUS by Gene and Tissue Microarrays: Expression Accompanies Progression. (2006) (0)
Expression of Myeloma-Specific Markers in Bone Marrow Spicules Using a Novel Immunohistochemical Technique (2008) (0)
OP52 The pursuit of cure in multiple myeloma (MM) – the Arkansas approach (2007) (0)
Use of genudtryksprofilering to predict survival in cancer patients (2005) (0)
prognostic relevance of the expression of its receptor The role of IGF-1 as a major growth factor for myeloma cell lines and the (2009) (0)
Increasing Wnt3a Signaling in Myeloma Cells Inhibits the Osteolytic Phenotype and Tumor Growth In Vivo through Regulation of the RANKL/OPG Axis in Osteoblasts and Indirectly Regulates Osteoclastogenesis. (2007) (0)
disease heterogeneity , cytogenetic status , and overall survival Telomerase and telomere length in multiple myeloma : correlations with (2003) (0)
B557 Molecular Pathogenesis of MGUS and Multiple Myeloma (2009) (0)
Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma. (2009) (0)
Cell lines of hyperdiploid myeloma, are we there yet? – response to Chng & Fonseca (2008) (0)
RFP2 Knockdown Disrupts Cell Growth and Induces Apoptosis in Multiple Myeloma (2008) (0)
Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma. (2005) (0)
Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells. (2004) (0)
Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total therapies 2 and 3. (2009) (0)
Abnormally High Levels of E- and N-Cadherin Expression Add to Altered Regulation of b-Catenin In Multiple Myeloma (2010) (0)
Global gene expression profiling clearly differentiates mouse plasma cell tumors from B-cell lymphomas but shows similarities with human multiple myelomas (2006) (0)
Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years. (2005) (0)
N-Cadherin Expressing MM Cells Form Calcium-Dependent, Adherent Junctions That Likely Contribute to Focal Lesions and Nodular Growth of Multiple Myeloma Cells (2010) (0)
Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (0)
DKK 1 as a universal myeloma antigen DKK 1 IS A WIDELY EXPRESSED AND POTENT TUMOR-ASSOCIATED ANTIGEN IN MULTIPLE MYELOMA (2007) (0)
prognosis to therapy define an aggressive multiple myeloma subtype with poor High serum-free light chain levels and their rapid reduction in response (2011) (0)
Myeloma and Osteolytic Bone Disease: Is DKK1 All It Takes?. (2008) (0)
Running Head: Wnt Inhibits Myeloma in Bone (2013) (0)
report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma (2008) (0)
JNK Regulates DKK1 Expression in Multiple Myeloma Cells. (2006) (0)
Inhibition of CKS1B Expression Affects Myeloma Cell Growth In Vivo. (2006) (0)
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2. (2008) (0)
induces spontaneous humoral and cellular immune responses NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and (2013) (0)
Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone (2010) (0)
Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil ( Cellcept ) in Advanced Multiple Myeloma Patients (2004) (0)
Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM). (2004) (0)
N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma (2021) (0)
Human Placenta-Derived Adherent Stem Cells Prevent Bone Loss and Stimulate Bone Formation in Myelomatous Bones, and Suppress Growth of Primary Multiple Myeloma (2008) (0)
B033 Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma (2009) (0)
Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis. (2005) (0)
Soluble and Membrane Bound MICA in Myeloma Do Not Adversely Effect Regulation of Natural Killer Cell Function Via NKG2D.. (2004) (0)
OP49 Multiple myelomas – dissecting distinct biological entities by gene expression profiling of plasma cells and microenviroment (2007) (0)
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022) (0)
Bone Morphogenic Protein 6: A Prognostic Factor Expressed by Normal Plasma Cells and Multiple Myeloma Cells Inhibiting Their Proliferation and Angiogenesis Induction (2008) (0)
CKS1B, Mapping to an Amplicon on Chromosome 1q21 and over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through p27 Kip1 -Dependent and Independent Mechanisms. (2006) (0)
Heparanase Upregulates Synthesis and Expression of Syndecan-1 (CD138) - A Novel Growth Regulatory Loop for Myeloma Tumors. (2005) (0)
NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma. (2004) (0)
Systemically Injected Mesenchymal Stem Cells Traffic to Myelomatous Bone and Inhibit Bone Disease, and Intralesionally Promotes Bone Formation and Delays Myeloma Progression During the Disease Active Stage or Remission (2010) (0)
Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials (2022) (0)
Systematic analysis and display of oligonucleotide microarray based global gene expression data with SPSS 80 software (2000) (0)
Dendritic cells support long term survival of plasma cells via CD28-CD80/CD86 interactions (66.11) (2011) (0)
Mapping of international protein index to Affymetrix probe-set identifier for correlating genomics and proteomics expression profiles in multiple myeloma (2011) (0)
Novel prognosis prediction model for human breast cancer patients based on a heterologous tissue culture gene expression signature (2007) (0)
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components. (2010) (0)
Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide (2011) (0)
Beta-Catenin and N-Cadherin in Myeloma: Implications for Adhesion and Migration. (2005) (0)
CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction (2020) (0)
Toward Defining the Functional Relevance of Wnt Signaling in Osteoclasts in Multiple Myeloma. (2006) (0)
Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma (2020) (0)
Identification of Novel Transcriptional Consequences of Activation and Inactivation of TP53 in Multiple Myeloma. (2007) (0)
Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of M-CA for survival in total therapy protocols (TT1, TT2, TT3). (2010) (0)
RAR (cid:1) 2 expression is associated with disease progression and plays a crucial role in efﬁcacy of ATRA treatment in myeloma (2009) (0)
The BCL9 Oncogene Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic and Angiogenic Properties to Myeloma Cells (2008) (0)
MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2. (2006) (0)
IgM-expressing Waldenstrom's Macroglobulinemia tumor cells reveal a potential for isotype switch (2005) (0)
DKK-1 Is a Widely Expressed, Potent Tumor-Associated Antigen in Multiple Myeloma Recognized by Cytotoxic T Lymphocytes. (2005) (0)
B034 A Gene Expression—Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma (2009) (0)
SPOTLIGHT REVIEW The molecular characterization and clinical management of multiple myeloma in the post-genome era (2009) (0)
A Novel Mechanism for Intrachromosomal Gene Amplification in Multiple Myeloma: 1q12 Pericentromeric Heterochromatin Mediates Breakage- Fusion-Bridge Cycles of the 1q12~23 Amplicon (2008) (0)
Clinical, genomic, and imaging predictors of malignancy: Analysis of the first U.S. cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120). (2013) (0)
To the editor : Mutation , SNP , and isoform analysis of fibroblast growth factor receptor 3 ( FGFR 3 ) in 150 newly diagnosed multiple myeloma patients (0)
Chromosomal Translocation Chromosomal Translocation Mechanisms and Consequences of Mechanisms and Consequences of (2006) (0)
Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM). (2005) (0)
Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. (2023) (0)
enhances natural killer cell-mediated lysis of myeloma Bortezomib down-regulates the cell surface expression of HLA-class I and (2013) (0)
Conclusions of a seven-year translational research initiative: Defining and validating a molecular signature of high-risk multiple myeloma (2007) (0)
Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival (2011) (0)
ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (0)
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2023) (0)
other imaging techniques and prognostic factors in multiple myeloma F18-fluorodeoxyglucose positron emission tomography in the context of (2011) (0)
Curing Multiple Myeloma: Lessons from Total Therapy Protocols (2009) (0)
Bone marrow microenvironment (ME) associated genes identified prior to all altered 48 hours after bortexomib test-dose application and prognosis of multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (0)
Molecular analysis of sixteen unrelated factor XIIIA deficient families from south-east of Iran (2008) (0)
Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures. (2010) (0)
The Ellipticine Derivative NSC 338258 Has Anti-Myeloma Activity. (2005) (0)
RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma. (2009) (0)
cells gammopathy of undetermined significance, and normal bone marrow plasma Global gene expression profiling of multiple myeloma, monoclonal (2011) (0)
Gene Expression Profiles for Prognosis in MGUS, Coupled with Signatures of Oncogenic Pathway Deregulation Provide a Novel Approach for Selection of Molecular Targets in Multiple Myeloma. (2007) (0)
and tumor growth Wnt3a signaling within bone inhibits multiple myeloma bone disease (2008) (0)
Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk. (2010) (0)
DNA amplification and elevated expression of CKS1B is associated with reduced levels of p27Kip1 and poor survival in multiple myeloma (2005) (0)
Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma. (2004) (0)
’ s response to reviews Title : Gm 40600 suppressed SP 2 / 0 isograft tumor by reducing Blimp 1 and Xbp 1 proteins (2019) (0)
BIOLOGY OF MULTIPLE MYELOMA: ONCOGENE ACTI- VATION IN THE GERMINAL CENTER, AND A CRITICAL ROLE FOR CYCLIN D DYSREGULATION MULTIPLE (2005) (0)
Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone. (2010) (0)
Multicolor Spectral Karyotyping Identification of New Nonrandom Translocations in Multiple Myeloma With (2011) (0)
Thalidomide and Hematopoietic Stem Cell Transplantation for Multiple Myeloma (2006) (0)
Atacicept (TACI-Ig) Inhibits Growth of TACIhigh Primary Myeloma Cells in SCID-Hu Mice. (2006) (0)
Expression of Wnt-3a in Myeloma Cells Inhibits the Osteolytic Phenotype In-Vivo. (2006) (0)
New Insights into the Molecular Basis of Multiple Myeloma Pathogenesis and Prognosis (2009) (0)
Gene expression profiles defining molecular subtypes, coupled with signatures of tumor biology and chemotherapy sensitivity provide a novel therapuetic approach to multiple myeloma (2008) (0)
Predicting Event-Free and Overall Survival after Treatment of Myeloma with the Proteasome Inhibitor Bortezomib with Pre-Treatment and 48-Hour Post-Therapy Gene Expression Patterns. (2004) (0)
Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival. (2010) (0)
Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial (2010) (0)
Dkk1 Transgenic Mice for the Study of Bone Lesions in Human Multiple Myeloma. (2005) (0)
Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics. (2006) (0)
Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles (2016) (0)
The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials (2022) (0)
Manuscript-HPSE regulates syndecan levels (2007) (0)
Gene Expression Signature in MGUS and Multiple Myeloma (2013) (0)
Running title: Role of RAR 2 in multiple myeloma (2013) (0)
Advances in Multiple Myeloma Gene-Expression Profiling (2013) (0)
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022) (0)
The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation. (2009) (0)
Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V). (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John D. Jr. Shaughnessy?

John D. Jr. Shaughnessy is affiliated with the following schools:

University of Arkansas
University of Arkansas for Medical Sciences
Aarhus University
Icahn School of Medicine at Mount Sinai

John D. Jr. Shaughnessy's Academic­Influence.com Rankings

Why Is John D. Jr. Shaughnessy Influential?

John D. Jr. Shaughnessy's Published Works

Published Works

What Schools Are Affiliated With John D. Jr. Shaughnessy?

John D. Jr. Shaughnessy's AcademicInfluence.com Rankings